{"id":"W2037994583","doi":"10.1182/blood-2014-08-595801","title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Takeda Pharmaceuticals International; National Cancer Institute; Celgene; Sanofi; Pfizer","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Oncology; Refractory (planetary science); Hodgkin lymphoma; Lymphoma; Phases of clinical research; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002714173,0.0001822993,0.0005258002,0.0002348771,0.00003332568,0.00000788694,0.00008946018,0.00009244726,0.0001117922],"category_scores_gemma":[0.0003538439,0.0001323715,0.00006610523,0.0003771364,0.00002798264,0.00004323746,0.00004580109,0.00008610979,0.00001739032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001325246,"about_ca_system_score_gemma":0.0001903167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008391761,"about_ca_topic_score_gemma":0.0004807393,"domain_scores_codex":[0.9984515,0.0001414678,0.000513859,0.0003448095,0.0002752722,0.0002730368],"domain_scores_gemma":[0.9990339,0.0002102243,0.0001308583,0.0004504473,0.0000381449,0.0001364256],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002103406,0.235492,0.7202937,0.0001124501,0.0001928825,0.00148917,0.002632924,0.000005491856,0.009846725,0.00003951943,0.0004385261,0.0273532],"study_design_scores_gemma":[0.1993028,0.009180764,0.7790502,0.0005421412,0.0002932209,0.00009710922,0.00112191,0.0001385624,0.009223568,0.00002203879,0.0008364372,0.0001912759],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970829,0.0002151213,6.301418e-7,0.0001418785,0.00006334858,0.0007016107,0.00000692016,0.00002995472,0.00175757],"genre_scores_gemma":[0.999265,0.00003979175,0.0001647747,0.00005963857,0.00004282129,0.0001217427,0.00001382243,0.00002324197,0.0002692198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2263113,"threshold_uncertainty_score":0.5397951,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01928113197485227,"score_gpt":0.297972365067819,"score_spread":0.2786912330929667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}